The significantly higher CD38 expression on plasma cells and plasmablasts compared to other immune cells suggests the potential for selectively depleting these cells with an anti-CD38 monoclonal therapeutic antibody for treatment of patients with RA and SLE. This evidence concerns the gene CD38 and rheumatoid arthritis.